Opendata, web and dolomites

TEXAD SIGNED

TEXAD – Tailoring EXosomes for Autoimmune Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TEXAD" data sheet

The following table provides information about the project.

Coordinator
EXOGENUS THERAPEUTICS SA 

Organization address
address: PARQUE BIOCANT NUCLEO 04 LOTE 2
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 115˙000 €
 EC max contribution 115˙000 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-30   to  2020-12-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXOGENUS THERAPEUTICS SA PT (CANTANHEDE) coordinator 115˙000.00

Map

 Project objective

Exogenus Therapeutics is a drug development company using an exosome-based platform technology to develop an innovative pipeline of therapeutic products. Exogenus’ scientific team has pioneer research work in the area of Umbilical Cord Blood (UCB)-derived Extracellular Vesicles (EVs) clinical application. Among EVs, exosomes are nanosized vesicles (30-150nm) released from all types of cells responsible for cell-to-cell communication. Exogenus’ technology makes use of UCB cells preconditioned in ischemia, which secrete EVs enriched in pro-regenerative, anti-inflammatory and immunomodulatory biomolecules. Based on immunomodulatory properties of the lead biological active agent under development (Exo-101), and its capacity to increase immunotolerance, the company is investigating the potential of these vesicles for the treatment of autoimmune diseases. There are more than 80 different autoimmune diseases (AD) and a prevalence of more than 50 million people in the US alone. There is a high unmet need for most of these diseases, especially regarding safer treatments with less secondary effects. Based on their proprietary vesicles derived from UCB, Exogenus aims to develop a new generation of biologics for AD, with high efficacy and less secondary effects.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TEXAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TEXAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

bsnEA (2020)

Business Support Network – East Anatolia

Read More  

PROBIM (2020)

PRO Business Innovation Moldova

Read More  

INNCASTHUR-20_21 (2020)

Services addressing the innovation management capacity of SMEs in Thuringia

Read More